Mesothelioma Related Clinical Trials:
Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study

• Pharmacokinetic (PK) parameters Safety and tolerability (days 1-10) assessed by AEs, SAEs, labs, ECG reports, radiology reports.
  

• Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs) Safety and tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation
  

Inclusion criteria

1. Age ≥ 18 years
2. At time of diagnosis or relapse, histologically confirmed NSCLC with locally advanced or metastatic disease (stage IIIA, IIIB, or IV) or histologically confirmed mesothelioma of the pleura which is unresectable
3. Must have failed prior standard systemic therapy
   • NSCLC patients must have failed at least two prior therapies, including a platinum-based chemotherapy regimen
   • Malignant Pleural Mesothelioma patients must have failed at least one pemetrexed- or cisplatin-based chemotherapy regimen
4. Must have measurable disease (by computerized tomography [CT] or magnetic resonance imaging [MRI]) per disease specific criteria (RECIST criteria for NSCLC and modified RECIST criteria for mesothelioma)
5. Mesothelioma patients may have undergone pleurodesis
6. Written informed consent obtained prior to any screening procedures
7. Willingness to have multiple blood draws
8. Ability to swallow capsules or tablets

Exclusion criteria

1. Known brain metastases
2. Prior treatment with an HDAC inhibitor
3. Presence of clinically detectable third-space fluid collections (e.g., ascites or pleural effusions) that can be controlled by drainage or other procedures prior to study entry
4. Concomitant use of any anti-cancer therapy, including radiation therapy
5. Significant cardiac disease
6. Concomitant use of drugs with a risk of causing torsades de pointes
7. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
8. Previous use of monoamine oxidase inhibitors (e.g. clorgyline, iproniazid, isocarboxazid, moclobemide, sibutramine, phenelzine, tranylcypromine) within 14 days prior to the first dose of dextromethorphan

Other protocol-defined inclusion/exclusion criteria may apply